Background: Paraneoplastic syndromes are "remote" complications of cancer characterized clinically by neurological disease. The sera and cerebrospinal fluid (CSF) from patients with paraneoplastic neurological syndromes (PNS) frequently contain autoantibodies to illdefined neuronal antigens. We report here that neuronal glutamate receptors are targets for autoantibodies found in the serum from some patients with well-characterized
INTRODUCTION
Paraneoplastic neurological syndromes (PNS) are a "remote" complication of systemic cancer, Three major syndromes of paraneoplastic neurological injury have been described (2, (3) (4) 15) . Paraneoplastic cerebellar degeneration associated with gynecological and breast malignancies is characterized by cerebellar loss of Purkinje cells with variable loss of other neuronal populations. These patients exhibit an antibody response, termed Type I or anti-Yo, which labels antigens of 34 and 52 or 62 kD molecular weight in Western blots of Purkinje cell concentrates. Paraneoplastic encephalomyeloneuritis is associated with small cell carcinoma of the lung and is characterized pathologically by loss of neurons in brain, spinal cord, dorsal roots, and autonomic ganglia. These patients exhibit an antibody response, termed Type Ila or anti-Hu, which produces nuclear and cytoplasmic staining of virtually all neurons and neuronal proteins of [35] [36] [37] [38] [39] [40] [41] [42] kD in Western blots. Paraneoplastic ataxia/opsoclonus is believed to be associated with injury to brain stem omnipause neurons and is also associated with breast malignancies. This antibody response, termed, Type IIb or anti-Ri, stains nuclei and cytoplasm of virtually all neurons but, unlike Type Ila antibody response, labels antigens of 55 kD, and occasionally 70 kD, on Western blots of neuronal proteins. Each of these disorders may have its onset as long as 2 years prior to diagnosis of the underlying malignancy.
The detection of antineuronal antibodies in sera and CSF of patients with paraneoplastic neurological syndromes suggests that an autoimmune disorder may underlie these syndromes. Antibody-induced neuronal death of cultured cells in the absence of complement has supported a role for these agents in neurological injury (6) , but it is not known whether Type I, Ila, or IIb antibodies are themselves contributing directly to a role in the pathogenesis of these syndromes.
We have recently reported (13) that autoantibodies to the non-NMDA neuronal glutamate receptor subunit, GluR3 (7) , are present in patients with a rare form of childhood epilepsy, Rasmussen's encephalitis. In one patient, seizure frequency decreased following plasma exchange, which correlated with titers of anti-GluR3 antibodies. To Antibody specific for GluR5 was prepared from the serum of one patient by Western blot affinity chromatography as described previously (11) . In brief, GluR5 fusion protein (10 ,ug/lane) was size fractionated by sodium dodecyl sulfate gel electrophoresis and transferred to nitrocellulose. Nitrocellulose strips containing just the transferred fusion protein were then blocked with 4% dry milk in PBS for 1 hr at room temperature. Patient serum was then added to the Western blot strips (1:1000 dilution) and they were rocked overnight at 4°C. Strips were then washed repeatedly with PBS and for 2 min with sodium glycinate elution buffer (pH 3.0) before neutralizing with 1 M sodium phosphate buffer (pH 9.0). The antibody was then concentrated by Amicon filtration (50,000 MW cut-off) and quantitated using a BioRad protein assay. Development of Western blot strips for immunoreactivity as above confirmed the removal of GluR5-specific antibody. The recovery of active affinity purified antibody was verified by repeating the Western blot analysis as described for whole serum (not shown). For electrophysiology studies, affinity-purified antibody was exchanged five times during Amicon filtration with external electrophysiology solution as above.
RESULTS
Western Blot Analysis Western blot analysis of trpE-fusion proteins (see Materials and Methods) containing overlapping regions of the putative extracellular domain that precedes transmembrane 1 from GluRl, GluR2, GluR3, GluR5, or GluR6, and a domain of GluRl (Rlc) that exhibits high sequence identity with other GluRs was conducted. Serum samples were prepared and tested without knowledge of sample origin. Robust immunoreactivity to GluR5 fusion protein was detected in the serum from Patient 1 (see Fig. 1 (Fig. 1) , were not expected. In addition to staining of Purkinje cells ( Fig. 2A) , this serum produced highly specific regional staining of the lateral septum, bed nucleus of the stria terminalis, central nucleus of the amygdala, and the hippocampus (Fig. 2B) . Staining persisted to dilutions of 1:20,000. Compared with the staining pattern of antibodies prepared in rabbits to known non-NMDA GluR subunits (8,9,1 1) (Fig. 2B) , the pattern corresponds closely with GluR 1 (11) . Staining patterns suggestive of other glutamate receptor labeling were not detected in serum from other patients or controls. Also, affinity-purified antibody to GluR5 from Patient 1 reacted poorly with brain sections and failed to produce the pattern shown in Fig. 2 (not from this patient to GluR5 fusion protein on Western blots (Fig. 1) provided a simple method to obtain affinity-purified antibody for electrophysiological study. Affinity purified anti-GluRS IgG (330 ng/ml) produced enhancement of currents similar to' that produced by whole serum (Fig. 4A) (1) . The presence of autoantibodies to glutamate receptors that modulate receptor function in patients with paraneoplastic neurological syndromes may therefore be of functional significance. Subunit specificity of patient receptor autoantibodies also suggests a mechanism that would produce highly specific neuronal damage or death. For example, glutamate receptors on neurons expressing the appropriate GluR subunit(s), which are accessible to receptor-specific autoantibodies, would be subject to modulation. Enhancement of glutamate receptor activation, as would be expected in the presence of the autoantibodies identified in the present study, has been related to neuronal death through mechanisms of excitotoxicity. Consequently, only specific neurons, of specific receptor subunit composition, such as Purkinje cells that express GluRl, GluR5, and GluR6 (7), would be at risk, while other cells that do not express the appropriate subunits would be spared. Therefore, the sera of patients with' two very discrete neurological syndromes (paraneoplastic cerebellar degeneration, characterized by progressive destruction of Purkinje cells, and paraneoplastic opsoclonus/ataxia), possessing autoantibodies that recognize different GluR subunits, would be predicted to affect different neurons. Similar highly specific neuronal loss or dysfunction would also be'expected if antibodies affected receptor number at the cell surface'or if complement-mediated lysis was involved.
This study presents the second report in which autoantibodies to neuronal glutamate receptor subunit proteins have been detected in patients with progressive neurological disease. The autoreactivity to GluR receptor subunits observed in the present study differs from the autoimmune response previously described in patients with Rasmussen's encephalitis (13) in that sera from patients with paraneoplastic neurological syndromes recognize predominantly GluRl, GluR5, and GluR6, whereas sera from patients with Rasmussen's encephalitis react almost exclusively with GluR3. These observations raise questions as to whether antibodies to glutamate receptor subunits are present in other progressive neurological disorders as well. Examining other neurological diseases for the presence of autoantibodies to neurotransmitter receptors appears warranted.
